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Abstract
Betulinic Acid (BetA) and its derivatives have been extensively studied in the past for their anti-tumor effects, but relatively
little is known about its precursor Betulin (BE). We found that BE induces apoptosis utilizing a similar mechanism as BetA
and is prevented by cyclosporin A (CsA). BE induces cell death more rapidly as compared to BetA, but to achieve similar
amounts of cell death a considerably higher concentration of BE is needed. Interestingly, we observed that cholesterol
sensitized cells to BE-induced apoptosis, while there was no effect of cholesterol when combined with BetA. Despite the
significantly enhanced cytotoxicity, the mode of cell death was not changed as CsA completely abrogated cell death. These
results indicate that BE has potent anti-tumor activity especially in combination with cholesterol.
Citation: Mullauer FB, Kessler JH, Medema JP (2009) Betulin Is a Potent Anti-Tumor Agent that Is Enhanced by Cholesterol. PLoS ONE 4(4): e1. doi:10.1371/
journal.pone.0005361
Editor: Mikhail V. Blagosklonny, Ordway Research Institute, United States of America
Received February 12, 2009; Accepted March 23, 2009; Published April 28, 2009
Copyright:  2009 Mullauer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work is supported by the ‘‘stichting nationaal fonds tegen kanker’’ http://www.tegenkanker.nl/. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: J.P.Medema@amc.nl
Introduction
Triterpenoids are extensively studied for the potential use as
anticancer agents. One of the most promising compounds in this
class is Betulinic Acid (BetA), but its effect is limited by the poor
solubility of the compound. A lot of effort is therefore put into
the development of derivatives of BetA with the goal to develop
even more powerful compounds and to achieve better solubility
for enhanced in vivo administration [1–3]. BetA has been
modified at many different positions including C1-4, C-20, C-28
and A-, D- and E ring with different outcomes [2,4]. For
example, Kvasanica et al found 3beta-O-phthalic esters from
BetA more cytotoxic and polar in comparison to BetA itself [5].
In contrast, generation of different C-28 ester derivatives did not
result in enhanced cytotoxicity [4]. On the other hand, C-28
amino acid conjugates made by Jeong et al showed improved
selective toxicity and solubility [6] and a C-3 modified BetA
derivative has shown promising results in a human colon cancer
xenograft model [2].
BetA can be found in numerous different plants, but it can also
be obtained by a simple 2 step reaction from its more abundantly
available precursor molecule Betulin (BE) [3]. BE is easily isolated
and therefore plays an important role as raw material for the
production of BetA and other biologically active compounds [7].
BE itself has been shown in the past to only possess limited or no
cytotoxic effects on cancer cells [5,8]. For example it was shown to
be inactive against MEL-2 (melanoma) cells when compared to
other BetA derivatives [9]. Several other melanoma lines (G361,
SK-MEL-28) leukemia lines (HL60, U937, K562), and neuroblas-
toma (GOTO, NB-1) cell lines were also found to be more
resistant to BE than to other tested lupane triterpenes [10]. In
contrast, a recent report found BE to be active against colorectal
(DLD-1), breast (MCF7), prostate ( PC-3) and lung (A549 ) cancer
cell lines [11], and for A549 it was shown that apoptosis was
induced [12]. Apoptosis is one of the major cell death pathways
induced by anti tumor agents. In principle, two main pathways
can be distinguished, the extrinsic or death receptor pathway and
the intrinsic or mitochondrial pathway with the latter being
regulated by the Bcl-2 family of proteins [13]. Numerous studies
have shown that BetA induces apoptosis via the mitochondrial
pathway [14–17], however, to our knowledge, it is currently not
clear how BE induces cell death. Here we show that apoptosis
induction by BE does not involve the death receptor pathway, but
is dependent on the mitochondria. Nevertheless, similar as we
have previously shown for BetA [17], cytochrome c release and
caspase activation occur independently of the Bcl-2 family proteins
but are blocked in the presence of cyclosporin A (CsA), an
inhibitor of the mitochondrial permeability transition (PT) pore.
Furthermore we found that cholesterol strongly enhances the
cytotoxic effects induced by BE but not BetA. Our results suggest




Betulin ($98% pure; Sigma-Aldrich, St Louis, MO, USA) and
Betulinic Acid ($99% pure; BioSolutions Halle, Germany) were
dissolved in DMSO at 4 mg/ml, cholesterol (Sigma-Aldrich) was
dissolved at 5 mM in DMSO. Aliquots were kept frozen.
Propidium iodide (PI), zVAD.fmk (benzyloxycarbonyl-Val-Ala-
Asp-fluoromethylketone), etoposide and cyclosporin A were
purchased from Sigma-Aldrich, Mitosox was obtained from
Invitrogen (Carlsbad, CA, USA).
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Anti-PARP (#9542; Cell Signaling Technology, Danvers, MA,
USA) and anti-cytochrome c (clone 6H2.B4; BD Biosciences, San
Diego, CA, USA) were used.
Cell lines: A549 and Hela were obtained from the ATCC,
FADD-deficient, Caspase 8- deficient and control Jurkat cells (JA3)
were kindly provided by Dr John Blenis (Harvard Medical School,
Boston), Jurkat cells over-expressing Bcl-2 by Dr Jannie Borst
(NKI, Amsterdam) and Bax/Bak double knockout (DKO) mouse
embryonic fibroblasts (MEFs) and wild-type control MEFs were
from Dr Stanley Korsmeyer.
Cell death analysis
Overall cell death was assessed as previously described [18] by
PI exclusion assay. Briefly, cells were incubated with 1 mg/ml PI
and measured by flow cytometry.
DNA fragmentation
Cells were incubated in Nicoletti buffer containing 50 mg/ml PI
for at least 24 hours before analysis via flow cytometry.
Western blot analysis (immunoblotting)
Cells were lysed using Triton X-100 buffer and for protein
quantification a BCA kit from PIERCE was used. SDS-PAGE was
performed and proteins were transferred onto a PVDF transfer
membrane (Amersham Biosciences). Blocking of unspecific
binding sites was achieved by incubation of the membrane in
5% low fat milk powder in PBS/0.2% Tween-20 (blocking buffer)
for 1 hour at room temperature. Primary antibody incubation was
performed overnight at 4uC and secondary antibody (HRP
labeled) incubation for 2 hours at room temperature. For
chemiluminescent detection ECL from Amersham Biosciences
was used in combination with a LAS-3000 imaging system.
ROS detection
For ROS measurements the highly selective dye for mitochon-
drial superoxide Mitosox was used. Cells were incubated with 5
mM Mitosox in pre-warmed tissue culture medium at 37uC for 10
min before flow cytometry analysis.
Cytochrome c release by FACS staining
Cytochrome c release was measured as previously described by
Waterhouse et al [19]. First, outer cell membrane permeabiliza-
tion was achieved by incubation for 5–10 minutes with 50 mg/ml
digitonin in PBS containing 100 mM KCl. Cells were then fixed in
4% paraformaldehyde for 30 minutes at room temperature,
washed and incubated in blocking buffer (3% BSA, 0.05%
saponin, 0.02% azide in PBS supplemented with normal goat
serum, dilution 1:200). Anti cytochrome c incubation was done
overnight at 4uC and for flow cytometric detection a FITC
conjugated secondary antibody was applied.
MTT assay
cells were incubated in the presence of 40 mg/ml MTT reagent for
2 hours at 37uC. During the incubation period appearance of purple
formazan structures was followed by phase-contrast light microscopy.
Results
Cholesterol strongly enhances cytotoxic effects of BE but
not BetA
Previously we have shown that BetA induces cell death in Jurkat
T leukemia cells in a concentration and time-dependent fashion
[18]. Here we show that low concentrations (5 mg/ml) of BetA are
non toxic up to 48 hours incubation and show limited cell death
after 72 hours (Figure 1A). In contrast, when 7.5 mg/ml BetA or
more is used almost all cells are PI positive after 48 to 72 hours
(Figure 1A). To analyze whether Betulin (BE), the precursor of
BetA, is capable of inducing cell death we titrated BE on Jurkat T
Leukemia cells. In contrast to previous reports we show here that
BE is capable of killing cells, but required higher concentrations
than BetA. However, it appeared that cell death induced by BE is
more efficient after 12 hours when compared to BetA and
maximum cell death is achieved after 24 hours (Figure 1C).
We have found previously that when using the MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay to
measure BetA [18] or BE (unpublished data) induced cytotoxicity,
results were much more pronounced when compared to other
assays such as PI exclusion and clonogenic survival [18]. This
decrease in MTT conversion is likely the result of a direct effect
of BetA on the mitochondria and was accompanied by a
different morphological appearance of the formazan precipitates.
While normal formazan formation shows a punctuate appear-
ance, BetA and BE-induced formazan formation shows the rapid
appearance of needle-like structures on the cell surface (Figure
S1). Interestingly, cholesterol, which shares some structural
similarities with BE and BetA, has been reported to have a
comparable effect in the MTT assay [20–22] (Figure S1). This
suggests that cholesterol, BetA and BE may share common
targets in the cell. To clarify if this feature is related to the
cytotoxicity of these compounds we decided to analyze the effect
of cholesterol on cell death and combine cholesterol with either
BetA or BE and measure PI exclusion after various time points.
Cholesterol itself did not induce cell death in Jurkat cells
(Figure 1E) and it did not enhance cytotoxicity of BetA at all
time points measured (Figure 1B). However, the combination of
BE with cholesterol resulted in massive cell death in Jurkat cells
even when very small concentrations of BE were used (2.5 and 5
mg/ml BE, Figure 1D). To rule out that this is a cell type specific
effect we analyzed cell death in A549 (lung carcinoma) and
HeLa (cervical carcinoma) cells exposed to either BE or BE in
combination with cholesterol. Similar to what was observed with
the Jurkat cells, both solid cancer cell lines displayed massive cell
death when treated with the combination of BE and cholesterol,
whereas BE by itself showed only minor toxicity at the
concentration used (Figure 1F and 1G).
BE/Cholesterol induces apoptosis in Jurkat cells
To identify the nature of cell death induced by BE/Cholesterol
we investigated the apoptotic pathway. Apoptosis has been
previously reported to be the cell death pathway induced by BE
in A549 lung cancer cells [12]. We assessed DNA fragmentation as
an apoptosis read-out in Jurkat cells treated for 24 hours with
either cholesterol, BE or the combination of both. In cells treated
with cholesterol only, DNA fragmentation was completely absent
(Figure 2A), consistent with the lack of cell death. BE, at 5 mg/ml,
induced only moderate DNA fragmentation. However, when
combined with cholesterol DNA was clearly fragmented
(Figure 2A). To verify these results we performed immunoblotting
for the classical caspase target PARP and observed similar effects:
Upon BE treatment PARP was processed to some extent and this
was strongly enhanced by addition of cholesterol (Figure 2B).
Importantly, both, DNA fragmentation and PARP cleavage were
blocked when cells were pre-treated with zVAD.fmk (a pan-
caspase inhibitor) confirming that both are caspase-mediated
events (Figure 2A and 2B).
Betulin-Induced Death
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cholesterol induced apoptosis
Cholesterol is an important constituent of cell membranes
where it plays a crucial role in maintaining integrity and fluidity
[23]. In addition, cholesterol-enriched micro-domains, so called
lipid rafts, are important signal transduction platforms [24], which
have been related to apoptosis [25] and changes in plasma
cholesterol levels have been associated with Fas-FADD complex
formation and caspase-8 activation [26,27]. BetA has been shown
to induce apoptosis independently of the extrinsic pathway [28].
However, because of the strong apoptosis-enhancing effects of
cholesterol when combined with BE, we decided to investigate the
Figure 1. Cholesterol strongly enhances cytotoxic effects of BE but not BetA. Jurkat cells were treated with the indicated concentrations of
BetA (A), BetA in combination with 5 mM cholesterol (B), BE (C), BE in combination with 5 mM cholesterol (D) or various concentrations of cholesterol
only (E). Cell death was monitored after 12, 24, 48 and 72 hours using PI exclusion. A549 lung cancer (F) and HeLa cervix carcinoma (G) cell lines were
treated with 5 mM cholesterol (chol), 5 mg/ml BE (5 BE) or the combination of 5 mg/ml BE with 5 mM cholesterol (5 BE+chol) and after 24 hours cell
death was analyzed via PI exclusion.
doi:10.1371/journal.pone.0005361.g001
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cells either deficient for FADD or caspase-8. Recently we showed
that the FADD and caspase-8 deficient cells were completely
resistant to Fas-induced apoptosis [17]. Here this resistance was
further confirmed using TRAIL (Figure 3A). Despite the resistance
towards the extrinsic pathway, neither cell line showed decreased
DNA fragmentation when treated with BE/cholesterol (Figure 3B),
indicating that the death receptor pathway is not involved in BE/
cholesterol-induced apoptosis.
BE/cholesterol induced apoptosis is mechanistically
related to BetA induced apoptosis
BetA induced apoptosis has been clearly linked to the
mitochondria [14–17] with the consistently described features of
cytochrome c release and induction of reactive oxygen species
(ROS) [28–31]. These events were initially described to be Bcl-2
family dependent [15,16], however, our recent evidence suggests
only a minor role for the Bcl-2 family proteins. Instead we
proposed a direct effect on the PT-pore [17]. To test if BE/
cholesterol induces apoptosis via similar mechanisms as BetA we
investigated the mitochondrial pathway of apoptosis.
BE/cholesterol showed clear cytochrome c release in Jurkat
cells. Importantly, there was only a slight difference in cytochrome
c release in the Bcl-2 over-expressing cells (Figure 4A), but this
difference was statistically not significant (paired t-test). Jurkat cells
over-expressing Bcl-2 were completely resistant to etoposide
(Figure. 4A). In contrast to the lack of effect of Bcl-2 over-
expression, CsA provided almost complete protection (Figure 4A).
To determine if ROS are produced upon BE/cholesterol
treatment we used a dye specifically detecting mitochondrial
superoxide. Both wildtype as well as Bcl-2 over-expressing cells
showed clear increase in ROS, strikingly this was again abolished
in the presence of CsA (Figure 4B). To verify that these events
resemble the amount of apoptosis and overall cell death we
measured DNA fragmentation and PI exclusion respectively. Bcl-2
over-expression did not provide any protection whereas CsA
effectively prevented both, apoptosis and cell death (Figure 4C and
4D). In order to find out if Bcl-2 over-expression causes a delay in
apoptosis as is the case with BetA [17], we performed a kinetic
analysis. Cell death and DNA fragmentation were measured after
various time points from 0–24 hours. At all time points we did not
observe any difference in sensitivity to BE/cholesterol, further
underscoring the lack of inhibition by Bcl-2 (Figure 4E and 4F).
These results suggest that BE/cholesterol kills Jurkat cells by
inducing mitochondrial damage that leads to cytochrome c release
and apoptosis which is completely independent of Bcl-2.
Figure 2. BE/cholesterol induces apoptosis in Jurkat cells. (A) Jurkat cells were pretreated with 20 mM zVAD.fmk for at least one hour prior to
addition of either DMSO, 5 mM cholesterol (5 Chol), 5 mg/ml BE (5 BE) or 5 mg/ml BE in combination with 5 mM cholesterol (5 BE+chol). After 24 hours
DNA fragmentation was assessed by FACS analysis of propidium iodide (PI) stained nuclei. (B) Jurkat cells were treated as described in (A) but after 24
hours PARP cleavage was assessed by immunoblotting. The protein kinase ERK was used as a loading control.
doi:10.1371/journal.pone.0005361.g002
Figure 3. The death receptor pathway is not involved in BE/cholesterol induced apoptosis. Jurkat control (JA3), FADD deficient (FADD ko)
or caspase-8 deficient (Casp-8 ko) cells were treated with TRAIL (0.5 mg/ml plus 1 mg/ml anti-FLAG) (A) or with either 5 mM cholesterol (chol) or 5 mg/
ml BE in combination with 5 mM cholesterol (5 BE+chol) and after 24 hours DNA fragmentation was analyzed.
doi:10.1371/journal.pone.0005361.g003
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out if Bax and Bak are involved in BE/cholesterol induced
cytotoxicity we used Bax/Bak double-knockout (DKO) mouse
embryonic fibroblasts (MEFs). DKO MEFs are resistant to drugs
such as etoposide, staurosporine, UVC or actinomycin D, all
targeting the Bcl-2 family regulated mitochondrial pathway [32].
We measured PI exclusion and found DKO MEFs to be sensitive
to BE/cholesterol, as a control for the functionality of the cells
etoposide was included (Figure 5A). We assessed if apoptosis was
induced like in BetA treated cells by analyzing PARP cleavage.
PARP was clearly processed in wildtype as well as in DKO MEFs,
suggesting that Bax and Bak are not essential in BE/cholesterol
induced apoptosis (Figure 5B). Also cytochrome c release was not
prevented in DKO MEFs (Figure 5C), further substantiating that
Bax and Bak are not required for BE/cholesterol mediated
cytotoxicity. Similar to Jurkat cells, CsA provided complete
protection against cell death (Figure 5A), apoptosis (Figure 5B)
and cytochrome c release (Figure 5C), confirming the crucial role
Figure 4. BE/cholesterol induced apoptosis is not affected by Bcl-2 over-expression but is inhibited in the presence of cyclosporin
A. (A) Jurkat control (wt) or Bcl-2 over-expressing cells (Bcl-2) were treated as indicated (5BE=5 mg/ml BE; chol=5 mM cholesterol; CsA=5 mg/ml
cyclosporin A), after 24 hours intracellular staining for cytochrome c release was performed. (B, C, D) Jurkat control (wt) or Bcl-2 over-expressing cells
were treated with 5 mg/ml BE/ 5 mM cholesterol either in the absence or presence of 5 mg/ml cyclosporin A. After 24 hours ROS (B), DNA
fragmentation (C) and overall cell death (D) were assessed by FACS analysis. (E, F) Jurkat control (wt) or Bcl-2 over-expressing cells were treated with 5
mg/ml BE/ 5 mM cholesterol and PI exclusion (E) or DNA fragmentation (F) were measured after 0, 4, 8, 16 and 24 hours.
doi:10.1371/journal.pone.0005361.g004
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induced cytotoxicity.
Discussion
BE is a natural compound, which contains derivatives that have
been shown to possess strong anti-tumor properties [7,33]. Here
we provide evidence that BE itself, especially in combination with
cholesterol (BE/cholesterol), is very potent in killing cancer cells in
vitro (Figure 1). BE/cholesterol induces apoptosis in a similar
manner as BetA and does not involve the extrinsic pathway of
apoptosis (Figure 3), but instead apoptosis depends on the
mitochondrial pathway (Figure 4). However, as we reported for
BetA, this pathway is activated in an unconventional manner as
cytochrome c release and apoptosis are induced in cells over-
expressing Bcl-2 (Figure 4) or in cells deficient for Bax/Bak
(Figure 5), while both events are blocked by CsA (Figure 4 and
Figure 5). This indicates that permeability transition is pivotal in
the process of BE/cholesterol induced cytotoxicity.
Despite the strong similarities, and the almost identical structure
of BE and BetA, there are also important differences in
comparison to BetA induced apoptosis. We previously showed
that Bcl-2 over-expression delayed BetA-induced apoptosis[17],
but curiously in the case of BE/cholesterol it has very limited effect
on the amount of cytotoxicity induced (Figure 4). Furthermore,
CsA by itself provides much stronger protection in the case of BE/
cholesterol in Jurkat cells, while BetA treated Jurkat cells are only
completely protected when a combination of CsA with Bcl-2 over-
expression is used.
This difference between BetA and BE/cholesterol is even more
remarkable when considering the time dependency of cytotoxicity
of both molecules: For BetA the maximum effect requires around
48–72 hours and a dose of 7.5–10 mg/ml (Figure 1A and 1B),
while BE/cholesterol induced death is already maximum at 24
hours. Nevertheless, CsA is capable of providing efficient
protection.
Striking is the fact, that cholesterol strongly enhances the
cytotoxic effects of BE but not BetA (Figure 1B and 1D) whilst
being completely non-toxic on its own, even at very high
concentrations (Figure 1E). Currently we do not know the
mechanism by which cholesterol acts as a ‘‘cytotoxicity-amplifier’’
for BE but it likely involves membrane integrity. Cholesterol is
Figure 5. BE/cholesterol induced apoptosis is independent of Bax/Bak. (A) Wildtype (wt) or Bax/Bak double knockout (DKO) mouse
embryonic fibroblasts (MEFs) were treated as indicated and after 24 hours cell death was assessed by PI exclusion. Etoposide was included as a
control for functionality of the cells. (B) Wt or DKO MEFs were treated as indicated and after 24 hours cells were subjected to immunoblotting to
determine PARP processing. ERK was used as control for equal protein amounts. (C) Wt and DKO MEFs were treated as indicated for 24 hours before
measuring cytochrome c release by intracellular FACS staining.
doi:10.1371/journal.pone.0005361.g005
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changes in cholesterol content can affect the amount of BE that is
taken up by a cell.
The effect on MTT conversion to formazan (MTT measures
mitochondrial enzymatic activity [20,34]) by all three compounds,
BetA, BE and cholesterol, suggests a common target in the
mitochondria. Even though this is clearly not directly related to
cytotoxicity, as cholesterol on its own is completely non-toxic, it
may point to a mechanism that sensitizes cells to BE. It is not clear
how this is orchestrated but it could involve the mitochondrial
membrane, for instance mitochondrial PT pore opening. The
exact composition of the pore has yet to be established but
adenine-nucleotide-translocator (ANT), voltage-dependent-anion-
channel (VDAC) and cyclophilin D are discussed as core
components in the currently accepted model [35]. PT pore
opening is influenced by the amount of cholesterol present in the
mitochondrial membrane, cholesterol affects VDAC function [35]
and impairs ANT mediated PT through altered membrane fluidity
[36]. So cholesterol-induced effects on the PT pore may facilitate
BE-induced opening. Why this then does not influence BetA-
induced opening is unclear at this point and will require further
investigation. In this light it is also important to realize that Bcl-2
over-expression delays BetA-induced apoptosis [17], while CsA
can only partially prevent the induction of apoptosis. This suggests
that BetA may has a direct effect on the PT pore, which is blocked
by CsA and maybe also induces a more classical Bcl-2-dependent
pathway to cytochrome c release. This latter seems absent when
using BE and may be the reason these compounds react slightly
different to CsA and potentially also cholesterol.
To further evaluate the anti-tumor properties of BE/cholesterol
in vivo studies will be required. Preliminary results from a
pharmacokinetic study using triterpene extract (TE) mainly
consisting of Betulin suggest that it is safe; no signs of toxicity
were observed in rats or dogs in a subchronic toxicity study [37].
Another study investigated the effects of BE on the central nervous
system (CNS) with the conclusion that there was no effect of BE on
muscle tone and coordination in mice; doses up to 100 mg/kg
bodyweight were used [38]. Interestingly another study explored
the antinociceptive properties of Betulin in mice and results
suggest that it is even more active than aspirin and paracetamol
[39].
It will be interesting to explore the combined effects of BE and
cholesterol in vivo. Because cholesterol is ubiquitously present in the
body it is unlikely that additional applied cholesterol is useful for in
vivo effects of BE as an anti-tumor agent. Our results indicate that
the amount of cholesterol necessary (5 mM) for enhanced in vitro
effects of BE are about 1000 times lower than normal plasma
cholesterol levels in humans (5 mM). However the fast majority of
this cholesterol is contained in LDL or HDL and it is therefore
difficult to assess whether there is sufficient free cholesterol
available to potentiate BE-induced apoptosis in vivo. Adding more
cholesterol may not bear any significance though, but application
of cholesterol containing Betulin-liposomes may be an interesting
mode of applying this cytotoxic agent. In summary we conclude
that Betulin by itself and in combination with cholesterol is a
potent anti-cancer agent in vitro and warrants further investigation
in vivo.
Supporting Information
Figure S1 MTT conversion. Effects of BetA, cholesterol and BE
on MTT assay: Jurkat cells were treated as indicated, incubated
with MTT reagent and photographed under a phase-contrast
microscope.
Found at: doi:10.1371/journal.pone.0005361.s001 (6.51 MB TIF)
Acknowledgments
We would like to thank John Blenis, Jannie Borst, and Stanley Korsmeyer
for kindly providing cells.
Author Contributions
Conceived and designed the experiments: FM JHK JPM. Performed the
experiments: FM JPM. Analyzed the data: FM JHK JPM. Wrote the
paper: FM JPM.
References
1. Bi Y, Xu J, Wu X, Ye W, Yuan S, et al. (2007) Synthesis and cytotoxic activity of
17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives. Bioorg
Med Chem Lett 17: 1475–1478.
2. Rajendran P, Jaggi M, Singh MK, Mukherjee R, Burman AC (2008)
Pharmacological evaluation of C-3 modified Betulinic acid derivatives with
potent anticancer activity. Invest New Drugs 26: 25–34.
3. Cichewicz RH, Kouzi SA (2004) Chemistry, biological activity, and chemo-
therapeutic potential of betulinic acid for the prevention and treatment of cancer
and HIV infection. Med Res Rev 24: 90–114.
4. Mukherjee R, Kumar V, Srivastava SK, Agarwal SK, Burman AC (2006)
Betulinic acid derivatives as anticancer agents: structure activity relationship.
Anticancer Agents Med Chem 6: 271–279.
5. Kvasnica M, Sarek J, Klinotova E, Dzubak P, Hajduch M (2005) Synthesis of
phthalates of betulinic acid and betulin with cytotoxic activity. Bioorg Med
Chem 13: 3447–3454.
6. Jeong HJ, Chai HB, Park SY, Kim DS (1999) Preparation of amino acid
conjugates of betulinic acid with activity against human melanoma. Bioorg Med
Chem Lett 9: 1201–1204.
7. Alakurtti S, Makela T, Koskimies S, Yli-Kauhaluoma J (2006) Pharmacological
properties of the ubiquitous natural product betulin. Eur J Pharm Sci 29: 1–13.
8. Gao H, Wu L, Kuroyanagi M, Harada K, Kawahara N, et al. (2003) Antitumor-
promoting constituents from Chaenomeles sinensis KOEHNE and their
activities in JB6 mouse epidermal cells. Chem Pharm Bull (Tokyo) 51:
1318–1321.
9. Kim DS, Pezzuto JM, Pisha E (1998) Synthesis of betulinic acid derivatives with
activity against human melanoma. Bioorg Med Chem Lett 8: 1707–1712.
10. Hata K, Hori K, Ogasawara H, Takahashi S (2003) Anti-leukemia activities of
Lup-28-al-20(29)-en-3-one, a lupane triterpene. Toxicol Lett 143: 1–7.
11. Gauthier C, Legault J, Lavoie S, Rondeau S, Tremblay S, et al. (2009) Synthesis
and cytotoxicity of bidesmosidic betulin and betulinic acid saponins. J Nat Prod
72: 72–81.
12. Pyo JS, Roh SH, Kim DK, Lee JG, Lee YY, et al. (2009) Anti-Cancer Effect of
Betulin on a Human Lung Cancer Cell Line: A Pharmacoproteomic Approach
Using 2 D SDS PAGE Coupled with Nano-HPLC Tandem Mass Spectrometry.
Planta Med 75: 127–131.
13. Jin Z, El-Deiry WS (2005) Overview of cell death signaling pathways. Cancer
Biol Ther 4: 139–163.
14. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, et al. (1998)
Activation of mitochondria and release of mitochondrial apoptogenic factors by
betulinic acid. J Biol Chem 273: 33942–33948.
15. Fulda S, Susin SA, Kroemer G, Debatin KM (1998) Molecular ordering of
apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 58:
4453–4460.
16. Fulda S, Debatin KM (2000) Betulinic acid induces apoptosis through a direct
effect on mitochondria in neuroectodermal tumors. Med Pediatr Oncol 35:
616–618.
17. Mullauer FB, Kessler JH, Medema JP (2009) Betulinic acid induces cytochrome
c release and apoptosis in a Bax/Bak-independent, permeability transition pore
dependent fashion. Apoptosis 14: 191–202.
18. Kessler JH, Mullauer FB, de Roo GM, Medema JP (2007) Broad in vitro efficacy
of plant-derived betulinic acid against cell lines derived from the most prevalent
human cancer types. Cancer Lett 251: 132–145.
19. Waterhouse NJ, Trapani JA (2003) A new quantitative assay for cytochrome c
release in apoptotic cells. Cell Death Differ 10: 853–855.
20. Abe K, Saito H (1998) Amyloid beta protein inhibits cellular MTT reduction not
by suppression of mitochondrial succinate dehydrogenase but by acceleration of
MTT formazan exocytosis in cultured rat cortical astrocytes. Neurosci Res 31:
295–305.
21. Abe K, Saito H (1999) Cholesterol does not affect the toxicity of amyloid beta
fragment but mimics its effect on MTT formazan exocytosis in cultured rat
hippocampal neurons. Neurosci Res 35: 165–174.
Betulin-Induced Death
PLoS ONE | www.plosone.org 7 April 2009 | Volume 4 | Issue 4 | e536122. Ahmad S, Ahmad A, Schneider KB, White CW (2006) Cholesterol interferes
with the MTT assay in human epithelial-like (A549) and endothelial (HLMVE
and HCAE) cells. Int J Toxicol 25: 17–23.
23. Mouritsen OG, Zuckermann MJ (2004) What’s so special about cholesterol?
Lipids 39: 1101–1113.
24. Helms JB, Zurzolo C (2004) Lipids as targeting signals: lipid rafts and
intracellular trafficking. Traffic 5: 247–254.
25. Malorni W, Giammarioli AM, Garofalo T, Sorice M (2007) Dynamics of lipid
raft components during lymphocyte apoptosis: the paradigmatic role of GD3.
Apoptosis 12: 941–949.
26. Mollinedo F, Gajate C (2006) Fas/CD95 death receptor and lipid rafts: new
targets for apoptosis-directed cancer therapy. Drug Resist Updat 9: 51–73.
27. Gniadecki R (2004) Depletion of membrane cholesterol causes ligand-
independent activation of Fas and apoptosis. Biochem Biophys Res Commun
320: 165–169.
28. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, et al. (1997) Betulinic acid
triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of
caspases in neuroectodermal tumors. Cancer Res 57: 4956–4964.
29. Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M (1999) Betulinic
acid-induced apoptosis in glioma cells: A sequential requirement for new protein
synthesis, formation of reactive oxygen species, and caspase processing.
J Pharmacol Exp Ther 289: 1306–1312.
30. Yamashita K, Lu H, Lu J, Chen G, Yokoyama T, et al. (2002) Effect of three
triterpenoids, lupeol, betulin, and betulinic acid on the stimulus-induced
superoxide generation and tyrosyl phosphorylation of proteins in human
neutrophils. Clin Chim Acta 325: 91–96.
31. Tan Y, Yu R, Pezzuto JM (2003) Betulinic acid-induced programmed cell death
in human melanoma cells involves mitogen-activated protein kinase activation.
Clin Cancer Res 9: 2866–2875.
32. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, et al. (2001)
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction
and death. Science 292: 727–730.
33. Sarek J, Kvasnica M, Urban M, Klinot J, Hajduch M (2005) Correlation of
cytotoxic activity of betulinines and their hydroxy analogues. Bioorg Med Chem
Lett 15: 4196–4200.
34. Slater TF, Sawyer B, Straeuli U (1963) Studies on Succinate-Tetrazolium
Reductase Systems. III. Points of Coupling of Four Different Tetrazolium Salts.
Biochim Biophys Acta 77: 383–393.
35. Grimm S, Brdiczka D (2007) The permeability transition pore in cell death.
Apoptosis 12: 841–855.
36. Colell A, Garcia-Ruiz C, Lluis JM, Coll O, Mari M, et al. (2003) Cholesterol
impairs the adenine nucleotide translocator-mediated mitochondrial permeabil-
ity transition through altered membrane fluidity. J Biol Chem 278:
33928–33935.
37. Jager S, Laszczyk MN, Scheffler A (2008) A preliminary pharmacokinetic study
of betulin, the main pentacyclic triterpene from extract of outer bark of birch
(Betulae alba cortex). Molecules 13: 3224–3235.
38. Muceniece R, Saleniece K, Rumaks J, Krigere L, Dzirkale Z, et al. (2008)
Betulin binds to gamma-aminobutyric acid receptors and exerts anticonvulsant
action in mice. Pharmacol Biochem Behav 90: 712–716.
39. de Souza MT, Buzzi FC, Cechinel FV, Hess S, Della MF, et al. (2007)
Phytochemical and antinociceptive properties of Matayba elaeagnoides Radlk.
barks. Z Naturforsch [C] 62: 550–554.
Betulin-Induced Death
PLoS ONE | www.plosone.org 8 April 2009 | Volume 4 | Issue 4 | e5361